GlassScriptPhysician profile
William R Sheldon, JR.
NPI 1386651180
$5,689.14
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,491 · 2020: $1,505 · 2021: $568 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,506.90 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $1,367.96 | 2019-2021 | |
| Mannkind Corporation | $326.19 | 2019-2020 | |
| Amgen INC. | $316.29 | 2019-2020 | |
| Lilly USA, LLC | $313.32 | 2019-2021 | |
| Abbvie INC. | $283.65 | 2019-2021 | |
| Novo Nordisk INC | $235.17 | 2019-2020 | |
| Radius Health, INC. | $155.30 | 2019-2021 | |
| Ibsa Pharma INC. | $150.01 | 2019-2024 | Tirosint |
| Amarin Pharma, INC. | $145.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.23 | 2019-2020 | |
| Insulet Corporation | $120.71 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $88.74 | 2019-2021 | |
| Valeritas, INC. | $68.91 | 2019 | |
| Dexcom, INC. | $65.44 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $52.63 | 2020-2021 | |
| Zealand Pharma US, INC. | $45.72 | 2021 | |
| Corcept Therapeutics | $42.64 | 2019 | |
| Pfizer INC. | $41.36 | 2019 | |
| Amneal Pharmaceuticals LLC | $40.79 | 2019-2020 | |
| Kvk-Tech, INC. | $33.55 | 2019 | |
| Antares Pharma, INC. | $30.70 | 2019-2020 | |
| Medtronic Minimed, INC. | $28.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.27 | 2019 | |
| Tandem Diabetes Care, INC. | $20.53 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.02 | 2020 | |
| Grt US Holding, INC. | $16.99 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.22 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sheldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.